Haematologica

Công bố khoa học tiêu biểu

* Dữ liệu chỉ mang tính chất tham khảo

Sắp xếp:  
Sequential loss of tumor surface antigens following chimeric antigen receptor T-cell therapies in diffuse large B-cell lymphoma
Haematologica - Tập 103 Số 5 - Trang e215-e218 - 2018
Haneen Shalabi, Ira L. Kraft, Hao‐Wei Wang, Constance M. Yuan, Bonnie Yates, Cindy Delbrook, Julie D. Zimbelman, Roger Giller, Maryalice Stetler‐Stevenson, Elaine S. Jaffe, Daniel W. Lee, Jack F. Shern, Terry J. Fry, Nirali N. Shah
Retroviral transfer of human CD20 as a suicide gene for adoptive T-cell therapy
Haematologica - Tập 94 Số 9 - Trang 1316-1320 - 2009
Marieke Griffioen, Esther H.M. van Egmond, Michel G.D. Kester, Roel Willemze, JH Falkenburg, Mirjam H.M. Heemskerk
Oncogenic D816V-KIT signaling in mast cells causes persistent IL-6 production
Haematologica - Tập 105 Số 1 - Trang 124-135 - 2020
Araceli Tobío, Geethani Bandara, Denise A. Morris, Do‐Kyun Kim, Michael P. O’Connell, Hirsh D. Komarow, Melody C. Carter, Daniel Smrž, Dean D. Metcalfe, Ana Olivera
Myelodysplastic syndromes: moving towards personalized management
Haematologica - Tập 105 Số 7 - Trang 1765-1779
Eva Hellström‐Lindberg, Magnus Tobiasson, Peter L. Greenberg
The myelodysplastic syndromes (MDS) share their origin in the hematopoietic stem cell but have otherwise very heterogeneous biological and genetic characteristics. Clinical features are dominated by cytopenia and a substantial risk for progression to acute myeloid leukemia. According to the World Health Organization, MDS is defined by cytopenia, bone marrow dysplasia and certain karyotypic abnormalities. The understanding of disease pathogenesis has undergone major development with the implementation of next-generation sequencing and a closer integration of morphology, cytogenetics and molecular genetics is currently paving the way for improved classification and prognostication. True precision medicine is still in the future for MDS and the development of novel therapeutic compounds with a propensity to markedly change patients’ outcome lags behind that for many other blood cancers. Treatment of higher-risk MDS is dominated by monotherapy with hypomethylating agents but novel combinations are currently being evaluated in clinical trials. Agents that stimulate erythropoiesis continue to be first-line treatment for the anemia of lower-risk MDS but luspatercept has shown promise as second-line therapy for sideroblastic MDS and lenalidomide is an established second-line treatment for del(5q) lower-risk MDS. The only potentially curative option for MDS is hematopoietic stem cell transplantation, until recently associated with a relatively high risk of transplant-related mortality and relapse. However, recent studies show increased cure rates due to better tools to target the malignant clone with less toxicity. This review provides a comprehensive overview of the current status of the clinical evaluation, biology and therapeutic interventions for this spectrum of disorders.
Efficacy, safety and survival with ruxolitinib in patients with myelofibrosis: results of a median 2-year follow-up of COMFORT-I
Haematologica - Tập 98 Số 12 - Trang 1865-1871 - 2013
Srđan Verstovšek, Ruben A. Mesa, Jason Gotlib, Richard S. Levy, Vikas Gupta, John F. DiPersio, John Catalano, Michael W. Deininger, Carole B. Miller, Richard T. Silver, Moshe Talpaz, EF Winton, John Collins Harvey, Murat O. Arcasoy, Elizabeth O. Hexner, Roger M. Lyons, Ronald Paquette, Azra Raza, Kris Vaddi, Susan Erickson‐Viitanen, William Sun, Victor Sandor, H. Kantarjian
Efficacy, safety, and survival with ruxolitinib in patients with myelofibrosis: results of a median 3-year follow-up of COMFORT-I
Haematologica - Tập 100 Số 4 - Trang 479-488 - 2015
Srđan Verstovšek, Ruben A. Mesa, Jason Gotlib, R. S. Levy, Vikas Gupta, John F. DiPersio, John Catalano, Michael W. Deininger, Carole B. Miller, Richard T. Silver, Moshe Talpaz, EF Winton, John Collins Harvey, Murat O. Arcasoy, Elizabeth O. Hexner, Roger M. Lyons, Azra Raza, Kris Vaddi, William Sun, Wei Peng, Victor Sandor, Hagop M. Kantarjian
Next-generation sequencing-based multigene mutational screening for acute myeloid leukemia using MiSeq: applicability for diagnostics and disease monitoring
Haematologica - Tập 99 Số 3 - Trang 465-473 - 2014
Raja Luthra, Keyur P. Patel, Neelima G. Reddy, Varan Haghshenas, Mark J. Routbort, Michael A. Harmon, Bedia A. Barkoh, Rashmi Kanagal‐Shamanna, Farhad Ravandi, Jorge E. Cortés, Hagop M. Kantarjian, L. Jeffrey Medeiros, Rajesh R. Singh
Regulation of PTEN by CK2 and Notch1 in primary T-cell acute lymphoblastic leukemia: rationale for combined use of CK2- and -secretase inhibitors
Haematologica - Tập 95 Số 4 - Trang 674-678 - 2010
A. Silva, Patrícia Yoshioka Jotta, André B. Silveira, Daniel Ribeiro, Sílvia Regina Brandalise, José Andrés Yunes, João T. Barata
Physical activity and risk of venous thromboembolism. The Tromso study
Haematologica - Tập 95 Số 12 - Trang 2088-2094 - 2010
Knut H. Borch, Ida J Hansen-Krone, Sigrid K. Brækkan, E. B. Mathiesen, Inger Njølstad, Tom Wilsgaard, J.-B. Hansen
Multisystem autoimmune disease caused by increased STAT3 phosphorylation and dysregulated gene expression
Haematologica - Tập 104 Số 7 - Trang e322-e325 - 2019
Francesca Todaro, Nicola Tamassia, Marinella Pinelli, Daniele Moratto, Laura Dotta, Alessia Grassi, Filippo Consonni, Mauro Giacomelli, Paolo Lionetti, Elisa Gardiman, Marco A. Cassatella, Eleonora Gambineri, Roberto Berni Canani, Raffaele Badolato
Tổng số: 62   
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7